Key features and details
- Mouse monoclonal [E1-2.5] to EBV Nuclear Antigen/EBNA1
- Suitable for: ICC, ELISA
- Isotype: IgG2b
Product nameAnti-EBV Nuclear Antigen/EBNA1 antibody [E1-2.5]
See all EBV Nuclear Antigen/EBNA1 primary antibodies
DescriptionMouse monoclonal [E1-2.5] to EBV Nuclear Antigen/EBNA1
SpecificityRecognizes repetitive gly-ala region of the nuclear antigen 1 of Epstein Barr virus (EBNA-1).
Tested applicationsSuitable for: ICC, ELISAmore details
Species reactivityReacts with: Other species
Other Immunogen Type. Nuclear antigen EBNA-1
Database link: P03211
This product was previously labelled as EBV Nuclear Antigen
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.097% Sodium azide
Concentration information loading...
PurityProtein A purified
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab8329 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ICC: Use at an assay dependant dilution.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceEpstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.
Cellular localizationNuclear. Free in the nucleoplasm, somewhat associated with the chromatin and hardly, if at all associated with the nuclear matrix.
- EBNA1 antibody
- EBV nuclear antigen 1 antibody
- Epstein Barr nuclear antigen 1 antibody
ab8329 has been referenced in 7 publications.
- Wang H et al. The Hsp70 inhibitor 2-phenylethynesulfonamide inhibits replication and carcinogenicity of Epstein-Barr virus by inhibiting the molecular chaperone function of Hsp70. Cell Death Dis 9:734 (2018). PubMed: 29959331
- Wang C et al. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism. Oncol Rep 37:2109-2120 (2017). PubMed: 28259949
- Ni C et al. In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Cell Res 25:785-800 (2015). PubMed: 25916549
- Cardinaud S et al. The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One 5:e8692 (2010). PubMed: 20098683
- Fawzy S et al. Detection of Epstein-Barr virus in breast carcinoma in Egyptian women. Clin Biochem 41:486-92 (2008). IHC-P . PubMed: 18258188
- Haque T et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110:1123-31 (2007). IHC-P . PubMed: 17468341
- McClain MT et al. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 54:360-8 (2006). PubMed: 16385527